Monthly Archives: March 2008

ACC News Echoes Cost/Benefit Concerns

News flowing from the American College of Cardiology meeting has been dominated by Vytorin. And after the presentation analyzing results yesterday, Miller Tabak analyst Les Fundleyter says, “We’re done for the conference in terms of the important stuff. Vytorin is the story this year.” So what is Vytorin’s story exactly? Industry watchers say they are […]
Posted in Meetings, R&D, Regulatory | 1 Comment

e-Pedigree: Delay, Delay, Delay

Looks like pharma companies and wholesalers will have two more years to get the kinks worked out of their electronic pedigree system. The California State Board of Pharmacy just announced that it would delay its e-pedigree law that would require all drugs that pass through the state to be electronically tracked. The date has been […]
Posted in Supply Chain, Technology | 4 Comments

HIV Ignored?
South Park and AIDS Foundation Think So

Looks like everyone is fair game on the Comedy Central show South Park–even Big Pharma. In one of the show’s funniest and most irreverent episodes to date, Eric Cartman (the potty-mouthed chubby kid with the poof-ball hat) becomes infected with HIV during a routine tonsillectomy. And it turns out nobody cares. Eric goes on an […]
Posted in Corporate Responsibility, Regulatory | 1 Comment

Secrets of the Dealmakers Revealed . . .

I had a chance late last week to moderate a panel at the Healthcare Dealmaking Symposium, sponsored by our friends at The Deal. My panelists, Annarie Lyles, SVP and Head of Corporate Development for Genmab, and Robert Knowles, Senior Director of Worldwide Business Development for Pfizer, had some very interesting insights into the state of […]
Posted in Deals | Leave a comment

Heparin Contaminant Identified

After weeks of questions and few answers, FDA has identified the contaminant in batches of Baxter’s blood-thinner heparin as over-sulfated chondroitin sulfate, a modified version of a biologically derived compound not found in heparin. The over-sulfated compound found in the batches is unnatural and is more than likely chemically modified, Janet Woodcock, director of FDA’s […]
Posted in Manufacturing | Leave a comment
  • Categories

  • Meta